EP300 and prostate carcinoma: Furthermore, for activity against prostate cancer, anacardic acids inhibit the proliferation and apoptosis of prostate cancer cells and hence induces cell cycle arrest such that it activates P53 signaling, inhibits NFκB, IkBa kinase and androgen receptors (AR), thereby suppressing p300 [38].